Stockreport

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Forte Biosciences, Inc.  (FBRX) 
PDF Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata DALLAS--(BUSINESS WIRE [Read more]